AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: moomoo
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIM
Wall Street analysts forecast AIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.694
Low
22.00
Averages
22.00
High
22.00
Current: 0.694
Low
22.00
Averages
22.00
High
22.00
No data
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIM ImmunoTech Completes Rights Offering Raising $1.8 Million
- Successful Rights Offering: AIM ImmunoTech announced the successful completion of its rights offering, raising approximately $1.8 million, reflecting market confidence in its product, particularly in addressing the global health challenge of late-stage pancreatic cancer.
- Unit Structure Details: Each right allowed holders to purchase one unit at a subscription price of $1,000, consisting of one share of Series G Convertible Preferred Stock and 2,000 Common Stock Purchase Warrants, providing investors with potential upside and strengthening the company's capital base.
- Regulatory Compliance Progress: The company's registration statement was declared effective by the SEC on February 10, 2026, enhancing the legitimacy and transparency of its fundraising efforts, thereby bolstering investor confidence.
- Future Development Outlook: AIM ImmunoTech focuses on the development of Ampligen®, a dsRNA and TLR3 agonist, which may play a significant role in treating various viral diseases and cancers, although extensive clinical trials are still required to validate its efficacy.
See More
AIM ImmunoTech Closes $1.8 Million Rights Offering
- Successful Rights Offering: AIM ImmunoTech announced the successful closing of its rights offering, resulting in total subscriptions of approximately $1.8 million, reflecting investor confidence in the company's future, particularly in its research for late-stage pancreatic cancer treatment.
- Unit Composition Details: Each right allowed holders to purchase one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and 2,000 Common Stock Purchase Warrants, enhancing the company's capital structure flexibility.
- Regulatory Compliance Progress: The company's registration statement was declared effective by the SEC on February 10, 2026, further ensuring the legality and transparency of the rights offering, which boosts investor trust.
- Future Development Outlook: AIM ImmunoTech remains focused on the development of Ampligen®, and while facing challenges in multiple clinical trials, the successful fundraising will provide necessary financial support for ongoing research, aiding the company's long-term strategic positioning in the immuno-pharmaceutical sector.
See More
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
AIM ImmunoTech Announces Rights Offering Details
- Rights Offering Initiation: AIM ImmunoTech has announced that its rights offering commenced on February 11, 2026, and is expected to expire on February 27, 2026; if fully subscribed, it anticipates raising $12 million, enhancing liquidity to support Ampligen® development.
- Subscription Rights Details: Each shareholder will receive one subscription right allowing them to purchase up to 12,000 units at $1,000 per unit, with each unit comprising one share of convertible preferred stock and 1,666 warrants, thereby increasing shareholder engagement and optimizing capital structure.
- Conversion and Exercise Terms: Each share of preferred stock can be converted into 833 shares of common stock at a conversion price of $1.20 per share, with warrants exercisable for five years post-issuance, ensuring shareholders have opportunities to increase their stake and strengthen the shareholder base.
- Regulatory Compliance: The rights offering is conducted in accordance with SEC registration statements, ensuring transparency and compliance, while shareholders must independently assess whether to exercise their rights, reflecting the company's commitment to shareholder interests.
See More
AIM ImmunoTech Launches Rights Offering for $12 Million
- Rights Offering Initiation: AIM ImmunoTech has launched a rights offering aiming to raise $12 million, demonstrating the company's commitment to addressing the global health challenge of late-stage pancreatic cancer treatment.
- Subscription Rights Allocation: Each shareholder will receive subscription rights based on their common stock holdings, allowing them to purchase up to 12,000 units at $1,000 per unit, enhancing shareholder engagement and liquidity.
- Oversubscription Privilege: Shareholders who fully exercise their basic subscription rights can subscribe for additional units, with remaining units allocated pro-rata among over-subscribers, ensuring fairness and incentivizing active participation.
- Defined Offering Period: The subscription rights are exercisable from February 11 to February 27, 2026, with unexercised rights expiring, emphasizing the importance of timely decision-making for shareholders in their investment strategies.
See More
AIM ImmunoTech to Participate in Corporate Connect Webinar
- Webinar Participation: AIM ImmunoTech will participate in the Corporate Connect Webinar hosted by Webull Financial on February 11, 2026, at 1:40 PM EST, where CEO Thomas K. Equels will provide a corporate overview and business outlook, emphasizing the company's strategic focus on pancreatic cancer.
- Strategic Focus: The presentation will highlight AIM's strategic emphasis on pancreatic cancer treatment, showcasing the latest advancements in its immunotherapy research, aimed at boosting investor confidence in the company's future potential.
- Product Introduction: AIM's lead product, Ampligen®, is a first-in-class investigational drug acting as a TLR3 agonist, currently undergoing clinical trials for various cancers and viral diseases, demonstrating broad therapeutic potential.
- Investor Relations: Through this webinar, AIM ImmunoTech aims to engage with investors, showcasing its innovative capabilities in cancer treatment and seeking to attract more investor attention towards its R&D progress and market outlook.
See More
AIM ImmunoTech Completes Rights Offering Raising $1.8 Million
- Successful Rights Offering: AIM ImmunoTech announced the successful completion of its rights offering, raising approximately $1.8 million, reflecting market confidence in its product, particularly in addressing the global health challenge of late-stage pancreatic cancer.
- Unit Structure Details: Each right allowed holders to purchase one unit at a subscription price of $1,000, consisting of one share of Series G Convertible Preferred Stock and 2,000 Common Stock Purchase Warrants, providing investors with potential upside and strengthening the company's capital base.
- Regulatory Compliance Progress: The company's registration statement was declared effective by the SEC on February 10, 2026, enhancing the legitimacy and transparency of its fundraising efforts, thereby bolstering investor confidence.
- Future Development Outlook: AIM ImmunoTech focuses on the development of Ampligen®, a dsRNA and TLR3 agonist, which may play a significant role in treating various viral diseases and cancers, although extensive clinical trials are still required to validate its efficacy.
See More
AIM ImmunoTech Closes $1.8 Million Rights Offering
- Successful Rights Offering: AIM ImmunoTech announced the successful closing of its rights offering, resulting in total subscriptions of approximately $1.8 million, reflecting investor confidence in the company's future, particularly in its research for late-stage pancreatic cancer treatment.
- Unit Composition Details: Each right allowed holders to purchase one unit at a subscription price of $1,000, with each unit consisting of one share of Series G Convertible Preferred Stock and 2,000 Common Stock Purchase Warrants, enhancing the company's capital structure flexibility.
- Regulatory Compliance Progress: The company's registration statement was declared effective by the SEC on February 10, 2026, further ensuring the legality and transparency of the rights offering, which boosts investor trust.
- Future Development Outlook: AIM ImmunoTech remains focused on the development of Ampligen®, and while facing challenges in multiple clinical trials, the successful fundraising will provide necessary financial support for ongoing research, aiding the company's long-term strategic positioning in the immuno-pharmaceutical sector.
See More
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
AIM ImmunoTech Announces Rights Offering Details
- Rights Offering Initiation: AIM ImmunoTech has announced that its rights offering commenced on February 11, 2026, and is expected to expire on February 27, 2026; if fully subscribed, it anticipates raising $12 million, enhancing liquidity to support Ampligen® development.
- Subscription Rights Details: Each shareholder will receive one subscription right allowing them to purchase up to 12,000 units at $1,000 per unit, with each unit comprising one share of convertible preferred stock and 1,666 warrants, thereby increasing shareholder engagement and optimizing capital structure.
- Conversion and Exercise Terms: Each share of preferred stock can be converted into 833 shares of common stock at a conversion price of $1.20 per share, with warrants exercisable for five years post-issuance, ensuring shareholders have opportunities to increase their stake and strengthen the shareholder base.
- Regulatory Compliance: The rights offering is conducted in accordance with SEC registration statements, ensuring transparency and compliance, while shareholders must independently assess whether to exercise their rights, reflecting the company's commitment to shareholder interests.
See More
AIM ImmunoTech Launches Rights Offering for $12 Million
- Rights Offering Initiation: AIM ImmunoTech has launched a rights offering aiming to raise $12 million, demonstrating the company's commitment to addressing the global health challenge of late-stage pancreatic cancer treatment.
- Subscription Rights Allocation: Each shareholder will receive subscription rights based on their common stock holdings, allowing them to purchase up to 12,000 units at $1,000 per unit, enhancing shareholder engagement and liquidity.
- Oversubscription Privilege: Shareholders who fully exercise their basic subscription rights can subscribe for additional units, with remaining units allocated pro-rata among over-subscribers, ensuring fairness and incentivizing active participation.
- Defined Offering Period: The subscription rights are exercisable from February 11 to February 27, 2026, with unexercised rights expiring, emphasizing the importance of timely decision-making for shareholders in their investment strategies.
See More
AIM ImmunoTech to Participate in Corporate Connect Webinar
- Webinar Participation: AIM ImmunoTech will participate in the Corporate Connect Webinar hosted by Webull Financial on February 11, 2026, at 1:40 PM EST, where CEO Thomas K. Equels will provide a corporate overview and business outlook, emphasizing the company's strategic focus on pancreatic cancer.
- Strategic Focus: The presentation will highlight AIM's strategic emphasis on pancreatic cancer treatment, showcasing the latest advancements in its immunotherapy research, aimed at boosting investor confidence in the company's future potential.
- Product Introduction: AIM's lead product, Ampligen®, is a first-in-class investigational drug acting as a TLR3 agonist, currently undergoing clinical trials for various cancers and viral diseases, demonstrating broad therapeutic potential.
- Investor Relations: Through this webinar, AIM ImmunoTech aims to engage with investors, showcasing its innovative capabilities in cancer treatment and seeking to attract more investor attention towards its R&D progress and market outlook.
See More
